Spero Therapeutics Nears Potential Breakout with FDA Decision
AI Prediction of Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics is poised for a potential breakout with the upcoming FDA decision on tebipenem HBr, its lead asset for treating complicated urinary tract infections. The approval could redefine treatment standards and significantly impact the company's valuation.
Spero Therapeutics, a clinical-stage biopharmaceutical company, is nearing a pivotal moment with the FDA's decision on tebipenem HBr expected by June 18, 2026. This decision could potentially make tebipenem HBr the first oral carbapenem antibiotic available in the U.S., addressing a substantial unmet need in the treatment of complicated urinary tract infections including pyelonephritis. Approval could drive significant revenue growth, given the lack of oral treatment alternatives capable of addressing drug-resistant strains of bacteria. The market's anticipation of this decision, coupled with a solid financial position that alleviates near-term funding concerns, presents a promising investment opportunity. The expected FDA approval serves as a critical catalyst that could substantially re-rate the stock higher in the near term.
SPRO Report Information
Prediction Date2026-04-11
Close @ Prediction$2.67
Mkt Cap161m
IPO DateN/a
AI-derived Information
Recent News for SPRO
- Mar 26, 4:05 pm — Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update (GlobeNewswire)
- Mar 18, 4:05 pm — Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 (GlobeNewswire)
- Feb 4, 8:31 am — GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook (Zacks)
- Dec 19, 8:00 am — Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis (GlobeNewswire)
- Nov 28, 8:00 am — Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Nov 13, 4:05 pm — Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire)
- Nov 4, 4:05 pm — Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 (GlobeNewswire)
- Oct 21, 2:00 am — PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) (GlobeNewswire)
- Oct 14, 8:00 am — Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek (GlobeNewswire)
- Oct 10, 10:00 am — Best Momentum Stock to Buy for October 10th (Zacks)
- Oct 8, 11:23 am — Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease (Zacks)
- Aug 19, 9:35 am — Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround (Zacks)
NDAPR (News-Driven AI Prediction Revision) events for SPRO
-
Mar 26, 4:16 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: Catalyst progress.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest